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 Background Lymphoma is the leading cause of cancer-related death among HIV-infected patients in the antiretroviral therapy 
(ART) era.
 Methods We studied lymphoma patients in the Centers for AIDS Research Network of Integrated Clinical Systems from 
1996 until 2010. We examined differences stratified by histology and diagnosis year. Mortality and predictors of 
death were analyzed using Kaplan–Meier curves and Cox proportional hazards.
 Results Of 23 050 HIV-infected individuals, 476 (2.1%) developed lymphoma (79 [16.6%] Hodgkin lymphoma [HL]; 201 
[42.2%] diffuse large B-cell lymphoma [DLBCL]; 56 [11.8%] Burkitt lymphoma [BL]; 54 [11.3%] primary central nerv-
ous system lymphoma [PCNSL]; and 86 [18.1%] other non-Hodgkin lymphoma [NHL]). At diagnosis, HL patients 
had higher CD4 counts and lower HIV RNA than NHL patients. PCNSL patients had the lowest and BL patients had 
the highest CD4 counts among NHL categories. During the study period, CD4 count at lymphoma diagnosis pro-
gressively increased and HIV RNA decreased. Five-year survival was 61.6% for HL, 50.0% for BL, 44.1% for DLBCL, 
43.3% for other NHL, and 22.8% for PCNSL. Mortality was associated with age (adjusted hazard ratio [AHR] = 1.28 
per decade increase, 95% confidence interval [CI] = 1.06 to 1.54), lymphoma occurrence on ART (AHR = 2.21, 95% 
CI = 1.53 to 3.20), CD4 count (AHR = 0.81 per 100 cell/µL increase, 95% CI = 0.72 to 0.90), HIV RNA (AHR = 1.13 per 
log10copies/mL, 95% CI = 1.00 to 1.27), and histology but not earlier diagnosis year.
 Conclusions HIV-associated lymphoma is heterogeneous and changing, with less immunosuppression and greater HIV control 
at diagnosis. Stable survival and increased mortality for lymphoma occurring on ART call for greater biologic 
insights to improve outcomes.
  J Natl Cancer Inst;2013;105:1221–1229 
HIV infection increases risk of non-Hodgkin lymphoma (NHL) 
and Hodgkin lymphoma (HL) (1–3). In the antiretroviral ther-
apy (ART) era, NHL incidence initially declined but has since 
stabilized, whereas HL incidence has remained stable and even 
increased in some cohorts (1,2,4). Additionally, cancer has 
increased as a proportional cause of mortality among HIV-infected 
persons, now accounting for 25% to 35% of HIV-associated 
deaths, with lymphoma being the most frequent cancer-related 
cause (5–8).
Risk factors for NHL include lower CD4 count and greater 
HIV viremia (9–13). However, risk is heterogeneous across NHL 
categories, with risk for Burkitt lymphoma (BL) being highest with 
modest rather than severe immunosuppression (14). Risk for HL 
may also be highest with modest immunosuppression and soon 
after ART initiation (15,16). Variable risk by CD4 count across 
lymphoma subtypes may lead to histologic shifts over time with 
earlier use of ART (17).
In the ART era, chemotherapy clinical trials have demonstrated 
comparable outcomes for patients with HIV-associated NHL and 
HL as for patients without HIV (18–22). European observational 
studies have also reported survival after NHL and HL for HIV-
infected individuals similar to that for HIV-uninfected individu-
als (23–26). However, observational studies in the United States 
have found HIV to be independently associated with mortality 
after NHL (27). Existing studies have examined NHL and HL 
separately and have not studied trends since the modern ART era 
began. We therefore studied a large HIV-infected cohort in the 
United States to define temporal trends in the current ART era.
Methods
Patients
The Center for AIDS Research (CFAR) Network of Integrated 
Clinical Systems (CNICS) provides a clinical data repository for 
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point-of-care electronic medical record systems (28). The CNICS 
cohort includes more than 25 000 HIV-infected adults aged older 
than 18 years, receiving care from January 1, 1995, to the present, at 
eight United States CFAR sites (Case Western Reserve University; 
University of Alabama at Birmingham; University of California, 
San Francisco; University of Washington; University of California, 
San Diego; Fenway Health, affiliated with Harvard University; 
University of North Carolina; and Johns Hopkins University). 
CNICS is a dynamic cohort with approximately 1400 new patients 
enrolling and 13% of existing patients leaving care each year. 
Institutional review boards at each university have approved study 
protocols. We examined all individuals in CNICS with NHL or 
HL diagnosed between January 1, 1996, and December 31, 2010. 
Follow-up was administratively censored on December 31, 2010.
Procedures
After informed consent, standardized demographic and historical 
information, including prior diagnoses and antiretroviral treat-
ment, are collected upon CNICS entry. Once enrolled, data, 
including medications, laboratory values, and AIDS-defining and 
non-AIDS-defining conditions, are prospectively collected at each 
site and verified by medical record review. A standardized cancer 
diagnosis verification procedure has been established at all sites (8). 
Incident cancer diagnoses are reviewed for confirmation and to col-
lect information regarding type, histology, staging, and treatment 
from the medical record. If more than one lymphoma diagnosis 
or relapse was recorded, we analyzed only the first occurrence. 
Patients must attend HIV clinics at network sites to be enrolled 
in CNICS, although once enrolled, data are frequently available 
before cohort entry. To increase generalizability, we included indi-
viduals diagnosed with lymphoma before and after CNICS entry 
to avoid exclusion of patients newly diagnosed with HIV, out of 
care, or transferring HIV care at the time of lymphoma diagnosis. 
Mortality data in CNICS are obtained from clinic sources and con-
firmed by the Social Security Death Index. CD4 count and HIV 
RNA values at lymphoma diagnosis were defined as values clos-
est to diagnosis date beginning 3  months before until 3  months 
after. Nadir CD4 count was defined as the lowest CD4 count at 
any time on or before the date of CD4 at lymphoma diagnosis. 
Suppressed HIV RNA was defined as a value less than 400 copies/
mL. Hepatitis B coinfection was defined as any positive hepatitis 
B surface antigen or DNA result, and hepatitis C coinfection was 
defined as any positive hepatitis C antibody or RNA result before 
or until 6 months after lymphoma diagnosis. Lymphoma develop-
ing on ART was defined as receipt of any antiretroviral medication 
from 24 weeks before lymphoma diagnosis until 4 weeks before 
lymphoma diagnosis. Patients with remote ART exposure ending 
more than 24 weeks before lymphoma diagnosis or with ART initi-
ated less than 4 weeks before lymphoma diagnosis were classified 
as having lymphoma not occurring on ART.
Statistical Analysis
Differences in proportions, means, and medians between 
lymphoma categories were assessed using χ2 or Fisher exact tests, 
one-way analysis of variance, and Kruskal–Wallis tests, respectively. 
Trends in proportions, means, and medians across calendar years 
were assessed using the Cochran–Armitage and Spearman rank 
correlation tests. Mortality rates were calculated as number of 
deaths per 100 person-years of follow-up. Follow-up time was 
calculated from date of lymphoma diagnosis until administrative 
censoring, death, or loss to follow-up. Loss to follow-up date 
was assigned based on last date of any clinical activity in CNICS, 
including outpatient visits, medication prescriptions, or laboratory 
and radiologic studies. To minimize survival bias, patients with 
lymphoma diagnosed before CNICS enrollment were treated 
as late entries and contributed follow-up time only after cohort 
entry (29). Kaplan–Meier cumulative mortality curves were used to 
estimate probability of death for 5 years after lymphoma diagnosis. 
Differences in survival across lymphoma categories and diagnosis 
years were evaluated using the log-rank test. Cox proportional 
hazards modeling was used to examine risk factors for mortality, 
including sex, race/ethnicity, age, diagnosis year, HIV transmission 
risk factor, hepatitis B/C coinfection, prior AIDS illness, ART status, 
CD4 count, HIV RNA, and histology. The proportional hazards 
assumption was assessed graphically for each variable by examining 
the log–log survival plot and inclusion of interaction term by time. 
Detailed information regarding lymphoma treatment, stage, and 
other prognostic features were not available. All analyses were 
conducted using SAS version 9.2 (SAS Institute, Cary, NC). A two-
sided alpha value of 0.05 was used to assess statistical significance. 
Patients were excluded from analyses that included variables for 
which data were missing. Sensitivity analyses, as well as analyses 
restricted to patients with lymphoma diagnosis after CNICS 
enrollment, were performed. Sex and race/ethnicity were included 
as covariables in all analyses. We did not do separate analyses by sex 
or racial/ethnic group.
results
Among 23 050 HIV-infected individuals enrolled in CNICS, 476 
(2.1%) individuals were diagnosed with lymphoma between 1996 
and 2010 (79 [16.6%] HL; 201 [42.2%] diffuse large B-cell lym-
phoma [DLBCL]; 56 [11.8%] BL; 54 [11.3%] primary central 
nervous system lymphoma [PCNSL]; 86 [18.1%] other NHL). Of 
these, 199 (41.8%) were diagnosed a median of 4.5 months (inter-
quartile range [IQR]  =  1.2–24.2) before CNICS enrollment. At 
lymphoma diagnosis, CD4 count and HIV RNA measurements 
differed from lymphoma diagnosis date by a median of 12  days 
(IQR = 4–27) and 13 days (IQR = 4–29), respectively. Patients with 
lymphoma diagnosed before CNICS enrollment were more likely 
to have missing data regarding CD4 count at diagnosis, nadir CD4 
count, or HIV RNA at diagnosis compared with patients for whom 
lymphoma was diagnosed after cohort entry (44.7% vs 11.9%; P < 
.001). Lymphoma developed on ART in 223 (47.0%) patients. At 
lymphoma diagnosis, these patients had a higher proportion with 
prior AIDS illness (89.2% vs 74.6%; P < .001), similar median CD4 
count (157 vs 103 cells/µL; P = .18), similar nadir CD4 count (52 
vs 67 cells/µL; P = .19), lower HIV RNA (2.30 vs 4.91 log10copies/
mL; P < .001), and higher proportion with suppressed HIV RNA 
(57.2% vs 5.3%; P < .001), compared with patients not on ART.
Baseline characteristics by lymphoma category are shown in 
Table 1. Pairwise comparisons demonstrated that HL patients were 
more likely than NHL patients at diagnosis to have black race/eth-
nicity, be on ART, have higher CD4 counts, have lower HIV RNA, 
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and have suppressed HIV RNA. Among NHL categories, PCNSL 
patients were more likely to be male (P < .001), be black (P = .003), 
have lower nadir CD4 count (P < .001), and have lower CD4 count 
at diagnosis (P < .001) than NHL patients without PCNSL. BL 
patients had higher nadir CD4 count (P = .006) and CD4 count at 
diagnosis (P < .001) than NHL patients without BL.
Proportional distribution of lymphoma categories by diagno-
sis year is shown in Figure 1. No statistically significant trend was 
observed in proportional distribution of HL vs NHL (P  =  .32). 
Among NHL categories, a statistically significant proportional 
increase over time in BL was observed.
Table  2 demonstrates presenting characteristics among all 
patients stratified by lymphoma diagnosis year. More recently diag-
nosed patients were older and more likely to be male, of nonwhite/
nonblack ethnicity, and men who have sex with men. Additionally, 
more recently diagnosed patients were more likely to have prior 
AIDS illness and be on ART at lymphoma diagnosis, with higher 
CD4 counts and lower HIV RNA.
Among all 476 patients with HIV-associated lymphoma, 225 
deaths occurred during 1525 person-years of follow-up, yield-
ing a mortality rate of 14.8 deaths per 100 person-years (95% 
confidence interval [CI]  = 12.9 to 16.8). Mortality rates, along 
with estimated 2-year and 5-year overall survival, stratified by 
lymphoma category are shown in Table 3. Five-year survival was 
61.6% for HL, 50.0% for BL, 44.1% for DLBCL, 43.3% for 
other NHL, and 22.8% for PCNSL. Cumulative mortality for 
NHL vs HL, as well as for NHL categories, is shown in Figure 2, 
with statistically significant differences observed between NHL 
and HL (P < .001) and among NHL categories (P < .001). No 
statistically significant cumulative mortality differences were 
observed for patients stratified by lymphoma diagnosis year 
(1996–2000 vs 2001–2005 vs 2006–2010) among all patients 
(P = .10) or when patients with NHL (P = .12) and HL (P = .95) 
were examined separately.
Results of Cox proportional hazards modeling including all 
listed covariables are shown in Table  4. Results are shown for 
the full cohort, as well as the restricted cohort with lymphoma 
diagnosed after CNICS enrollment. Independent risk factors for 
mortality included older age (adjusted hazard ratio [AHR] = 1.28 
per decade increase, 95% CI  =  1.06 to 1.54), lymphoma occur-
rence during ART (AHR = 2.21, 95% CI = 1.53 to 3.20), lower 
CD4 count at lymphoma diagnosis (AHR = 0.81 per 100 cell/µL 
increase, 95% CI = 0.72 to 0.90), higher HIV RNA (AHR = 1.13 
per log10copies/mL, 95% CI = 1.00 to 1.27), and histologic cate-
gory. More recent diagnosis year was not associated with decreased 
mortality. The association of lymphoma occurring on ART with 
increased mortality was consistent even when ART exposure was 
defined as beginning 48 rather than 24 weeks before lymphoma 
diagnosis (AHR  =  2.27, 95% CI  =  1.58 to 3.28 in full cohort; 
AHR = 2.58, 95% CI = 1.62 to 4.11 in restricted cohort) and when 
nadir CD4 count was included in the model in place of CD4 count 
at diagnosis (AHR = 2.12, 95% CI = 1.46 to 3.08 in full cohort; 
AHR = 2.16, 95% CI = 1.38 to 3.37 in restricted cohort). When 
dichotomous HIV RNA less than 400 copies/mL at diagnosis (ie, 
suppressed vs unsuppressed) was included in place of continuous 
HIV RNA log10copies per milliliter, lymphoma occurrence on 
ART was associated with an adjusted hazard ratio of 2.27 (95% 
CI = 1.46 to 3.16) in the full cohort and an adjusted hazard ratio 
of 2.35 (95% CI = 1.52 to 3.65) in the restricted cohort, and HIV 
RNA suppression was associated with an adjusted hazard ratio of 
0.63 (95% CI = 0.43 to 0.93) in the full cohort and an adjusted 
hazard ratio of 0.66 (95% CI  =  0.43 to 0.99) in the restricted 
cohort. Other model results were similarly consistent across all 
sensitivity analyses.
Figure 1. Proportional distribution of 476 HIV-associated lymphomas 
in the Center for AIDS Research Network of Integrated Clinical Systems 
cohort by lymphoma diagnosis year, 1996 to 2010. *Cochran–Armitage 
Ptrend for Burkitt lymphoma (BL) proportion relative to diffuse large 
B-cell lymphoma (DLBCL) is .01, BL relative to primary central nervous 
system lymphoma (PCNSL) is .02, and BL relative to all non-BL Non-
Hodgkin lymphoma (NHL) is .02. For all other pairwise comparisons 
between lymphoma categories, Cochran–Armitage Ptrend is greater 
than .05. All reported statistical tests are two-sided. HL  =  Hodgkin 
lymphoma.
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Discussion
Our results, from a large, multicenter United States HIV-
infected cohort, demonstrate that HIV-associated lymphoma is 
changing in the modern ART era. First, patients are older, with 
an increasing proportion having nonwhite/nonblack ethnicity, a 
group primarily comprised of Latino patients, reflecting trends 
in the United States HIV-infected population as a whole (30,31). 
Second, patients continue to have severe antecedent immuno-
suppression evidenced by static nadir CD4 counts over time. 
However, CD4 counts and HIV RNA suppression at lymphoma 
diagnosis are steadily improving. Third, histologic shifts are 
occurring with an increasing proportion of BL relative to other 
NHL categories. These findings are consistent with data from 
the HIV/AIDS Cancer Match Study, which reported stable BL 
incidence and declining DLBCL and PCNSL incidence among 
persons with AIDS (17).
Our results also confirm statistically significant variations in pres-
entation and survival across lymphoma categories. HL patients had 
higher CD4 counts and more frequent HIV RNA suppression at 
diagnosis than NHL patients. PCNSL was associated with greater 
immunosuppression and BL lesser immunosuppression at diagnosis 
compared with other NHL categories. Regarding survival, 61.6% of 
patients with HIV-associated HL were alive 5 years after lymphoma 
diagnosis, compared with 50.0% for BL, 44.1% for DLBCL, 43.3% 
for other NHL, and 22.8% for PCNSL. These survival differences 
correlated with CD4 count differences at diagnosis, although histol-
ogy was independently associated with mortality in adjusted analyses. 
By comparison, 5-year survival for all United States adults aged less 
Table 2. Characteristics of 476 HIV-infected adults in the Center for AIDS Research Network of Integrated Clinical Systems cohort with 
lymphoma between 1996 and 2010, stratified by year of diagnosis*
Characteristics 1996–2000 2001–2005 2006–2010 P
Total, No. (%) 132 (27.7) 201 (42.2) 143 (30.0) ―
Age, years, at lymphoma diagnosis, mean (SD) 40.2 (7.6) 42.1 (8.7) 44.6 (9.4) <.001
Male, No. (%) 109 (82.6) 182 (90.6) 130 (90.9) .03
Race/ethnicity, No. (%)†
 White 77 (58.8) 90 (44.8) 71 (51.1) .22
 Black 43 (32.8) 71 (35.3) 38 (27.3) .32
 Other 11 (8.4) 40 (19.9) 30 (21.6) .005
HIV transmission risk factor, No. (%)
 MSM 53 (40.2) 95 (47.3) 76 (53.2) .03
 IDU 26 (19.7) 34 (16.9) 19 (13.3) .15
 MSM and IDU 4 (3.0) 7 (3.5) 2 (1.4) .39
 Heterosexual 46 (34.9) 69 (34.3) 45 (31.5) .55
 Other/Unknown 19 (14.4) 25 (12.4) 13 (9.1) .17
Hepatitis B/C coinfection, No. (%) 22 (16.7) 46 (22.9) 29 (20.3) .48
AIDS illness before lymphoma diagnosis, No. (%) 100 (75.8) 162 (80.6) 126 (88.1) .008
ART at lymphoma diagnosis, No. (%) 54 (40.1) 93 (46.5) 76 (53.2) .04
CD4 count, cells/µL, at lymphoma diagnosis, median (IQR)† 85 (25–217) 120 (41–277) 166 (52–346) .004
CD4 percentage at lymphoma diagnosis, median (IQR)† 9.4 (3.0–18.2) 11.0 (5.0–21.0) 15.8 (7.0–22.0) .005
CD4 count, cells/µL, nadir, median (IQR)† 50 (13–145) 54 (14–158) 73 (20–195) .32
HIV RNA, log10copies/mL, at lymphoma diagnosis, median (IQR)† 4.56 (2.66–5.29) 4.36 (2.30–5.24) 3.26 (1.40–4.97) .001
HIV RNA <400 copies/mL at lymphoma diagnosis, No. (%)† 18 (24.7) 45 (28.9) 54 (42.2) .006
* Differences in proportions, means, and medians across calendar years were assessed using the Cochran–Armitage and Spearman rank correlation tests. All 
statistical tests reported are two-sided. ART = antiretroviral therapy; IDU = injection drug use; IQR = interquartile range; MSM = men who have sex with men; 
SD = standard deviation.
† Missing observations by respective calendar periods 1996–2000/ 2001–2005/ 2006–2009: Race/ethnicity = 1 (1%)/0 (0%)/4 (3%); CD4 count at lymphoma 
diagnosis = 49 (37)/39 (19%)/9 (6%); CD4 percentage at lymphoma diagnosis = 64 (49%)/46 (23%)/13 (9%); CD4 count nadir = 36 (27%)/26 (13%)/3 (2%);  
HIV RNA at lymphoma diagnosis = 59 (45%)/45 (22%)/15 (10%).
Table  3. Mortality rates and 2- and 5-year survival estimates for 476 HIV-infected adults in the Center for AIDS Research Network of 
Integrated Clinical Systems cohort with lymphoma between 1996 and 2010*
Type of  
lymphoma
No. of  
persons Deaths Person-years
Mortality rate per 100 
person-years (95% CI)
2-year survival % 
(95% CI)
5-year survival % 
(95% CI)
All lymphoma 476 225 1525 14.8 (12.9 to 16.8) 52.5 (47.7 to 57.9) 44.0 (39.2 to 49.3)
HL 79 23 292 7.9 (5.2 to 11.9) 71.7 (61.3 to 83.9) 61.6 (50.2 to 75.6)
All NHL 397 202 1233 16.4 (14.3 to 18.8) 48.8 (43.6 to 54.7) 40.6 (35.6 to 46.5)
BL 56 22 151 14.5 (9.6 to 22.1) 53.1 (40.2 to 70.1) 50.0 (37.0 to 67.5)
PCNSL 54 41 117 35.0 (25.8 to 47.5) 24.4 (15.5 to 38.6) 22.8 (14.2 to 36.7)
DLBCL 201 100 674 14.8 (12.2 to 18.0) 55.6 (48.5 to 63.8) 44.1 (37.2 to 52.4)
Other NHL 86 39 290 13.4 (9.8 to 18.4) 50.5 (39.1 to 65.2) 43.3 (32.5 to 57.8)
* BL = Burkitt lymphoma; CI = confidence interval; DLBCL = diffuse large B-cell lymphoma; HL = Hodgkin lymphoma; NHL = Non-Hodgkin lymphoma; 
PCNSL = primary central nervous system lymphoma.
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Figure  2. Cumulative mortality over time for Hodgkin lymphoma vs 
non-Hodgkin lymphoma (A) and non-Hodgkin lymphoma categories (B). 
*Number at risk may increase over time as a result of patients enrolled 
in Center for AIDS Research Network of Integrated Clinical Systems 
after lymphoma diagnosis who were treated as late entries. BL=Burkitt 
lymphoma; DLBCL  =  diffuse large B-cell lymphoma; HL  =  Hodgkin 
lymphoma; NHL  =  Non-Hodgkin lymphoma; PCNSL  =  primary 
central nervous system lymphoma.
than 65 years with HL, BL, and DLBCL diagnosed between 2001 
and 2007 were 88.4%, 50.5%, and 68.7%, respectively (32). Our data 
therefore suggest that patients in CNICS with HL and DLBCL fare 
worse than HIV-uninfected patients, whereas BL patients may have 
comparable survival with nonelderly adult BL patients, although up 
to 40% of such patients may be HIV-infected (17).
Our analyses also suggest that despite improvements in CD4 
counts and HIV RNA suppression between 1996 and 2010, more 
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recent lymphoma diagnosis was not associated with improved sur-
vival among HIV-infected patients. Our study may have lacked 
sufficient follow-up time for more recently diagnosed patients to 
demonstrate survival differences, although multivariable modeling 
resulted in adjusted mortality hazard ratios for lymphoma diagnosis 
year very near the null value.
If survival has indeed remained static and inferior to HIV-
uninfected patients, there are many possible explanations. Patients 
in our cohort represent a large and diverse HIV-infected popula-
tion in routine care across the United States and may differ sub-
stantially from smaller, more homogeneous, uniformly treated 
clinical trial populations. Additionally, observational studies sug-
gesting outcomes for HIV-infected lymphoma patients similar to 
those for HIV-uninfected patients in the ART era are largely from 
Europe (23–26), whereas our results are similar to a large observa-
tional study of NHL patients in the United States demonstrating 
worse outcomes for those with HIV (27). Discordant findings may 
partially reflect differences in the HIV-infected populations and 
health-care systems in the United States and Europe, respectively. 
Other reasons for a lack of survival improvement may include con-
tinued presentation with advanced stage and poor performance sta-
tus (25,27,33), difficulty achieving stage-appropriate chemotherapy 
cumulative dose and dose intensity (25,33), reduced effectiveness or 
greater toxicity of chemotherapy due to ART interactions (34), dis-
continuity or suboptimal concentrations of ART due to chemother-
apy interactions (33,34), diminished immunologic response against 
malignant lymphocytes, intrinsically aggressive tumor biology, and 
mortality from lymphoma-unrelated causes. Treatment incorporat-
ing more intensive first-line and salvage chemotherapy, immuno-
therapy, radiotherapy, and high-dose therapy with autologous stem 
cell rescue may also be less frequently used in HIV-infected patients 
(33). However, most patients in CNICS were treated in academic 
settings where treatment likely tends toward greater intensity.
The association of lymphoma occurring on ART with increased 
mortality is also noteworthy. The reasons for this are unclear. 
Importantly, patients on ART at lymphoma diagnosis may not ben-
efit from positive effects on survival conferred by ART initiation in 
addition to lymphoma treatment. Exposure to ART at lymphoma 
diagnosis may also be a marker for more advanced HIV illness, 
although we adjusted for measures of HIV disease severity. Social 
and behavioral differences impacting survival, including adherence 
to treatment, may additionally exist between patients developing 
lymphoma on and off ART.
However, lymphoma that develops on ART may also be bio-
logically different from lymphoma that occurs in the context of 
uncontrolled HIV. In an analogous condition, posttransplant 
Table 4. Adjusted mortality hazard ratios for HIV-infected adults in the Center for AIDS Research Network of Integrated Clinical Systems 
(CNICS) cohort with lymphoma between 1996 and 2010*••
Characteristics
All patients (n = 350)†
Patients with lymphoma 
diagnosed after CNICS  
entry (n = 242)‡
Adjusted hazard 
ratio (95% CI) P
Adjusted hazard 
ratio (95% CI) P
Male sex 1.12 (0.62 to 2.01) .70 0.99 (0.51 to 1.94) .98
Non-white ethnicity 0.89 (0.64 to 1.23) .48 1.05 (0.71 to 1.55) .83
Age at lymphoma diagnosis, per decade 1.28 (1.06 to 1.54) .009 1.21 (0.97 to 1.52) .09
Lymphoma diagnosis year
 1996–2000 Referent ― Referent ―
 2001–2005 1.06 (0.73 to 1.56) .75 1.26 (0.78 to 2.00) .35
 2006–2009 0.93 (0.60 to 1.46) .76 1.00 (0.57 to 1.73) .99
HIV transmission risk factor
 Heterosexual Referent ― Referent ―
 MSM and IDU 0.58 (0.24 to 1.39) .22 0.59 (0.22 to 1.60) .30
 IDU 1.19 (0.68 to 2.09) .55 0.95 (0.45 to 2.04) .90
 MSM 1.97 (0.66 to 1.42) .87 1.01 (0.64 to 1.58) .97
 Other/ unknown 1.49 (0.90 to 2.48) .12 1.20 (0.58 to 2.51) .62
Hepatitis B/C coinfection 1.06 (0.72 to 1.54) .78 1.02 (0.58 to 2.51) .93
AIDS illness prior to lymphoma diagnosis 1.16 (0.76 to 1.78) .49 1.24 (0.68 to 2.27) .49
ART at lymphoma diagnosis 2.21 (1.53 to 3.20) <.001 2.24 (1.44 to 3.49) <.001
CD4 count at lymphoma diagnosis, per 100 cells/µL 0.81 (0.72 to 0.90) <.001 0.79 (0.69 to 0.89) <.001
HIV RNA, log10copies/mL, at lymphoma diagnosis 1.13 (1.00 to 1.27) .05 1.11 (0.97 to 1.27) .13
Lymphoma category
 PCNSL Referent ― Referent ―
 HL 0.30 (0.16 to 0.56) <.001 0.21 (0.10 to 0.44) <.001
 BL 0.72 (0.37 to 1.39) .32 0.66 (0.29 to 1.49) .32
 DLBCL 0.51 (0.32 to 0.83) .007 0.41 (0.24 to 0.71) .002
 Other NHL 0.58 (0.33 to 1.02) .59 0.50 (0.26 to 0.94) .03
* Statistical significance testing for Cox proportional hazard model estimates were assessed using the Wald χ2 test. All statistical tests reported are two-sided. 
ART = antiretroviral therapy; BL = Burkitt lymphoma; CI = confidence interval; DLBCL = diffuse large B-cell lymphoma; HL = Hodgkin lymphoma; NHL =  Non-Hodgkin 
lymphoma; PCNSL = primary central nervous system lymphoma.
† One hundred twenty-six of 476 patients (26%) with missing data excluded from Cox proportional hazards modeling.
‡ Thirty-five of 277 patients (13%) with missing data excluded from Cox proportional hazards modeling.
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lymphoproliferative disorder occurring more than 2  years after 
transplant is more frequently negative for Epstein–Barr virus, with 
a distinct gene expression pattern, and worse clinical outcome 
compared with early posttransplant lymphoproliferative disorder 
(35–38). Such differences have not been adequately investigated for 
HIV-associated lymphoma, and our findings highlight a need for 
continued basic investigations comparing tumors before and after 
ART to characterize molecular features and therapeutic targets for 
lymphoma occurring in both contexts.
Biologic mechanisms underlying histologic shifts are similarly 
unclear and likely involve complex interactions between viral onco-
gens such as Epstein–Barr virus (34), immune surveillance of trans-
formed lymphocytes in the germinal center (4,15), activation of cell 
signaling pathways such as nuclear factor-κB (4,15), and chronic 
B-cell activation (14,39), all of which likely vary in relative con-
tribution across histologic subtypes (29). Changes in lymphoma 
diagnostic methods have also occurred during the period studied, 
including increased use of fluorescence in situ hybridization to 
detect c-myc translocation in BL. These advances likely influence 
changes in histologic classifications over time.
Our research has several limitations. First, data are observational, 
and associations may be due to unmeasured confounding. Second, 
we included patients with lymphoma preceding CNICS enrollment, 
as well as those with missing data. We sought to maintain gener-
alizability to patients typically seen, including those not receiving 
HIV care or newly diagnosed with HIV at lymphoma diagnosis. 
We minimized bias by analyzing follow-up time only after CNICS 
entry and sought to ensure that immortal person-time between lym-
phoma diagnosis and cohort entry was not inappropriately counted. 
However, results remain susceptible to survival bias because survival 
for patients with lymphoma before CNICS enrollment may not be 
accurately reflected. Additionally, we performed sensitivity analyses 
and restricted analyses to patients with lymphoma diagnosed after 
CNICS enrollment and found consistent results. Third, detailed 
information regarding lymphoma presentation and treatment were 
not analyzed. We are implementing a centralized abstraction to 
collect detailed lymphoma data on all patients to examine correla-
tions between lymphoma presentation, treatment, and outcomes. 
Fourth, ART effects after lymphoma diagnosis were not analyzed. 
Correlations between HIV treatment and survival, including tim-
ing of ART initiation and differential effects of various ART regi-
mens, are the focus of ongoing analyses. Finally, cause of death was 
unknown, and our analyses focused on overall survival, although 
HIV-infected patients are at risk for competing causes of death.
Despite these limitations, our study has several strengths. To our 
knowledge, this is the first study from a large, multicenter cohort 
to describe temporal changes in presentation and outcomes among 
patients with HIV-associated NHL and HL since the beginning of 
the modern ART era. Patients studied represent a large and diverse 
HIV-infected population in routine care across the United States, 
undergoing regular assessment, in whom lymphoma diagnoses 
were rigorously verified to minimize misclassification. Additionally, 
mortality assessment used active and passive surveillance, leading 
to near-complete ascertainment.
In conclusion, HIV-associated lymphoma is highly heterogene-
ous in the current era, and important demographic, immunologic, 
virologic, and histologic shifts are occurring. In our analyses of a 
large US HIV-infected cohort, survival after lymphoma diagnosis 
has not statistically significantly improved since the modern ART 
era began, and outcomes remain inferior to registry data for the 
general population. These results highlight an ongoing need to 
elucidate lymphoma biology and optimize treatment for this chal-
lenging population to reduce deaths from one of the leading causes 
of mortality in the modern ART era.
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